EHA 2025: Real-World Insights on Belantamab Mafodotin in RRMM
/ Fredrik Schjesvold
EHA 2025: Overcoming Venetoclax Resistance
/ Justinas Daraskevicius
Several Options for Frontline Treatment of MCL
/ Mats Jerkeman